Insights

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, provide a comprehensive analysis of risk stratification in high-risk HR+/HER2- early-stage breast cancer, clinical approaches with high-risk breast cancer, recent trial data with CDK4/6 inhibitors, and strategies for managing toxicities for treatment continuity in the management of HR+/HER2- early-stage breast cancer, offering valuable insights to optimize patient care.

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss the nuanced treatment landscape of myelofibrosis, exploring the latest advancements in JAK inhibitors, the importance of individualized care, and the potential of emerging combination therapies to enhance patient outcomes.

Hana Safah, MD, and Corey Cutler, MD, MPH, review recent data in graft-vs-host disease and provide comprehensive insights on treatment practices.

Shirish Gadgeel, MD, and Benjamin Levy, MD, discuss recent updates in 2023 on antibody-drug conjugates for treating patients with advanced NSCLC as well as their clinical implications.

Kevin Kalinsky, MD, MS, and Erica L. Mayer, MD, MPH, provide comprehensive insights on the evolving treatment landscape for patients with HR+ breast cancer and ESR1 mutations.

A panel of oncology specialists explores the latest developments in HER2-directed ADCs for solid tumors, emphasizing the growing potential in gynecological cancers.

Edgardo Santos, MD, FACP, FCCP, clinical affiliate associate professor, Florida Atlantic University; Vice-President, Florida Society of Clinical Oncology, discusses key advancements made in treatment approaches for NSCLC in 2023.

Sergio Giralt, MD, provides a look at an upcoming OncLive Insights program in which he will offer insights on the evolving treatment landscape for patients with veno-occlusive disease.

Expert medical oncologists Laura Spring, MD, and Manali Bhave, MD, discuss recent advances in the treatment of HER2-positive and HER2-low breast cancer, present hypothetical patient cases, and discuss their treatment approaches to illustrate how to incorporate recent data into practice.

Experts Joyce O’Shaughnessy, MD, and Erin Cobain, MD, review the clinical evolution of treatments in early-stage breast cancers, highlighting the latest data in genomic testing presented at the SABCS 2023 annual congress.

A panel of three, renowned oncologists discuss the evolving landscape of CAR-T cell therapies for adult patients with relapsed or refractory acute lymphoblastic leukemia after receiving two or more lines of prior therapy.

A group of oncology experts discusses the adjuvant treatment of melanoma, providing expert insights into the management of immunotherapy-related endocrine and cardiac toxicities, with a case discussion to emphasize these important topics.

A team of oncology experts discuss how collaboration among healthcare professionals can optimize care and improve quality of life for patients with advanced stage prostate cancer.

Neal Shore, MD, FACS, and Rana McKay, MD, discuss recent advances in understanding and targeting androgen receptor signaling in metastatic prostate cancer and emerging treatment approaches.

Expert oncologists discuss the current treatment landscape and latest data in the treatment of patients with AL amyloidosis with cardiac involvement.

Edgardo Santos, MD, FACP, FCCP, clinical affiliate associate professor, Florida Atlantic University; Vice-President, Florida Society of Clinical Oncology, discusses key advancements in immunotherapy-based treatment approaches for NSCLC in 2023.

Expert Nicole Lamanna, MD, reviews the clinical evolution of targeted therapies in in B-cell malignancies, highlighting the latest data in CLL to be presented at the upcoming ASH 2023 annual congress.

Following ESMO 2023, a panel of experts on bladder cancer review recent updates and discuss the evolving treatment landscape, with a focus on non–muscle invasive bladder cancer.